Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

Article  CAS  PubMed  Google Scholar 

Nastoupil LJ, Bartlett NL. Navigating the evolving treatment landscape of diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(4):903–13. https://doi.org/10.1200/JCO.22.01848.

Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737–46. This comprehensive review describes in detail the three randomized phase 3 trials in second line LBCL, and why they represent a true paradigm shift in management.

Article  CAS  PubMed  Google Scholar 

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY12. J Clin Oncol. 2014;32(31):3490–6.

Article  CAS  PubMed  Google Scholar 

Flowers CR, Odejide OO. Sequencing therapy in relapsed DLBCL. Hematol Am Soc Hematol Educ Program. 2022;2022(1):146–54.

Article  Google Scholar 

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.

Article  CAS  PubMed  Google Scholar 

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.

Article  PubMed  PubMed Central  Google Scholar 

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordon MJ, Sureda A, Westin JR. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. Leuk Lymphoma. 2022;63(9):2041–51.

Article  CAS  PubMed  Google Scholar 

Gurumurthi A, Westin JR, Subklewe M. The race is on: bispecifics vs CAR T-cells in B-cell lymphoma. Blood Adv. 2023;7(19):5713–6. https://doi.org/10.1182/bloodadvances.2022009066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strati P, Gregory T, Majhail NS, Jain N. Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review. JCO Oncol Pract. 2023;19:OP2200819.

Google Scholar 

Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. 2023;41(Suppl 1):112–8.

Article  PubMed  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

Article  PubMed  Google Scholar 

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307–15.

CAS  PubMed  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–54.

Article  CAS  PubMed  Google Scholar 

Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629–39.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–84.

Article  CAS  PubMed  Google Scholar 

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148–57. This is the first trial in nearly 30 years to significantly improve overall survival in patients with second line LBCL.

Article  CAS  PubMed  Google Scholar 

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–308.

Article  CAS  PubMed  Google Scholar 

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066–77.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–42. This is the first trial to use CAR T-cell therapy for patients in first line therapy of LBCL, a potentially historic landmark which has resulted in randomized trials in this space.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, et al. Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma. J Clin Oncol. 2023;41:JCO2300570.

Article  Google Scholar 

Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, et al. Late Relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2019;37(21):1819–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D’Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, et al. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma. Clin Cancer Res. 2023;29(10):1894–905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, et al. Real-world evidence of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023;142:1055.

Article  Google Scholar 

Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108(1):110–21.

Article  CAS  PubMed  Google Scholar 

Efficace F, Cannella L, Sparano F, Giesinger JM, Vignetti M, Baron F, et al. Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review. Hemasphere. 2022;6(12):e802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sureda A, Lugtenburg PJ, Kersten MJ, Subklewe M, Spanjaart A, Shah NN, et al. Cellular therapy in lymphoma. Hematol Oncol. 2023. https://doi.org/10.1002/hon.3200.

Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022;140(21):2248–60.

Article  CAS